EKF.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 16:34):

Stats
Dagens volum	137 154
Gjennomsnittsvolum	312 504
Markedsverdi	135.67M
EPS	£0 ( 2024-03-25 )
Last Dividend	£1.200 ( 2022-11-02 )
Next Dividend	£0 ( N/A )
P/E	29.90
ATR14	£0.767 (2.57%)

EKF Diagnostics Holdings Korrelasjon

10 Mest positive korrelasjoner
MPL.L	0.932
PDL.L	0.924
TPX.L	0.923
OMIP.L	0.916
RDT.L	0.913
SCLP.L	0.913
3SNV.L	0.909
TBLD.L	0.909
3SUB.L	0.906
DSW.L	0.902

10 Mest negative korrelasjoner
AEXG.L	-0.959
EMR.L	-0.958
CFX.L	-0.957
INSE.L	-0.949
SPEC.L	-0.939
VAST.L	-0.939
SKL.L	-0.938
NWT.L	-0.934
IPF.L	-0.932
GRA.L	-0.926

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

EKF Diagnostics Holdings Økonomi

Annual	2023
Omsetning:	£52.61M
Bruttogevinst:	£24.44M (46.45 %)
EPS:	£0.00520

FY	2023
Omsetning:	£52.61M
Bruttogevinst:	£24.44M (46.45 %)
EPS:	£0.00520

FY	2022
Omsetning:	£66.64M
Bruttogevinst:	£24.04M (36.07 %)
EPS:	£-0.0209

FY	2021
Omsetning:	£81.84M
Bruttogevinst:	£39.37M (48.10 %)
EPS:	£0.0347

Financial Reports:

No articles found.

EKF Diagnostics Holdings Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£1.200 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

EKF Diagnostics Holdings Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.77 - good (97.65%) | Divividend Growth Potential Score: 5.27 - Stable (5.34%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£1.000	2020-11-04
Last Dividend	£1.200	2022-11-02
Next Dividend	£0	N/A
Payout Date	2022-12-01
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	£3.30	--
Avg. Dividend % Per Year	0.73%	--
Score	3.09	--
Div. Sustainability Score	9.77
Div.Growth Potential Score	5.27
Div. Directional Score	7.52	--

Next Divdend (Est)
(2024-09-30)

£0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.09

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2020	£1.000	2.98%
2021	£1.100	1.62%
2022	£1.200	1.58%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TYMN.L	Dividend Knight	2023-08-03	Annually	29	2.69%
MGCI.L	Dividend King	2023-08-03	Quarterly	6	3.54%
CTEC.L	Dividend Knight	2023-08-17	Semi-Annually	8	1.46%
SCP.L	Dividend Knight	2023-07-13	Semi-Annually	31	1.83%
HTG.L	Dividend King	2023-10-05	Semi-Annually	32	1.82%
BCPT.L	Dividend King	2023-09-14	Monthly	20	2.80%
WKP.L	Dividend Junior	2023-07-06	Annually	31	2.53%
NAIT.L	Dividend Knight	2023-07-20	Quarterly	53	2.33%
ECK.L	Dividend Knight	2023-09-21	Annually	14	0.93%
SOM.L	Dividend King	2023-09-21	Semi-Annually	18	5.37%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0447	1.500	9.11	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0291	1.200	9.03	10.00	[0 - 0.3]
returnOnEquityTTM	0.0358	1.500	-0.713	-1.070	[0.1 - 1]
payoutRatioTTM	2.32	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	2.69	0.800	1.545	1.236	[1 - 3]
quickRatioTTM	1.768	0.800	4.31	3.45	[0.8 - 2.5]
cashRatioTTM	0.814	1.500	6.59	9.89	[0.2 - 2]
debtRatioTTM	0.0507	-1.500	9.16	-10.00	[0 - 0.6]
interestCoverageTTM	63.41	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.0139	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.00146	2.00	-0.000732	-0.00146	[0 - 20]
debtEquityRatioTTM	0.0611	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.464	1.000	5.59	5.59	[0.2 - 0.8]
operatingProfitMarginTTM	0.0904	1.000	-0.192	-0.192	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.540	1.000	2.56	2.56	[0.2 - 2]
assetTurnoverTTM	0.651	0.800	9.00	7.20	[0.5 - 2]
Total Score				9.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	57.30	1.000	4.31	0	[1 - 100]
returnOnEquityTTM	0.0358	2.50	-0.458	-1.070	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00146	2.00	-0.000488	-0.00146	[0 - 30]
dividendYielPercentageTTM	4.04	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0139	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	2.32	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	57.30	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.120	1.000	9.50	0	[0.1 - 0.5]
Total Score				5.27

EKF Diagnostics Holdings

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.